Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer

Personalis, Inc.

2026-Q1 EPS reported -$0.29 vs consensus -$0.28 ▼ miss (-5.4%)

Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.
Cash, equivalents & short-term investments $233.2M; includes ~$21M net from ATM at $10.00/share.
Full-year 2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45k, net loss ~$105M.
Second Medicare coverage in six months (lung cancer surveillance) follows prior breast cancer win.
CEO states 'Win-in-MRD' strategy working; clinical revenue expected to grow five-fold in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Personalis, Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.